Evaluation of prognostic factors and treatment modalities in ovarian cancer patients with brain metastases

Noel Anupol, Sharad Ghamande, Kunle Odunsi, Deborah Driscoll, Shashikant Lele

Research output: Contribution to journalArticle

61 Citations (Scopus)

Abstract

Objective. The objective of this study is to evaluate the impact of different clinical variables and treatment modalities on survival in patients with brain metastases from ovarian carcinoma. Methods. Methods included: (1) retrospective chart review of all patients with ovarian cancer and brain metastases from 1986 to 2000 at Roswell Park Cancer Institute and (2) Medline search was performed to extract data from all published reports with three or more cases of ovarian cancer with brain metastases. Cox regression analysis, Kaplan-Meier test, and log rank test were used to calculate survival and compare the impacts of clinical variables and treatment modalities. Results. Fifteen patients with brain metastases out of 1042 women with ovarian carcinoma were identified from our institution, an incidence of 1.4%. The median time from initial diagnosis to detection of brain metastases was 22 months. Patients who were not treated after brain metastasis had a median survival of 0.5 month versus 6 months with therapy. In the subgroup of patients treated with a combination of radiation, surgery, and chemotherapy, the median survival was 22 months. Literature analysis combined with our data generated 124 patients. The only clinically significant variable impacting survival was the presence or absence of additional distant recurrence with median survivals of 3 and 8 months, respectively (P = 0.005). Among patients who received treatment, the combination of radiation and surgery with or without chemotherapy appears to be beneficial, with a median survival of 20 months (P < 0.001). Conclusion. Patients with brain metastases from ovarian cancer without any evidence of disease in other sites appear to benefit from aggressive combined treatment with external radiation and surgery with or without chemotherapy with a median survival of 20 months.

Original languageEnglish (US)
Pages (from-to)487-492
Number of pages6
JournalGynecologic Oncology
Volume85
Issue number3
DOIs
StatePublished - Jan 1 2002

Fingerprint

Ovarian Neoplasms
Neoplasm Metastasis
Survival
Brain
Therapeutics
Radiation
Drug Therapy
Brain Neoplasms
Carcinoma
Kaplan-Meier Estimate
Regression Analysis
Recurrence
Incidence
Neoplasms

Keywords

  • Brain metastases
  • Brain recurrence
  • Multimodality treatment
  • Ovarian carcinoma
  • Treatment of brain metastases

ASJC Scopus subject areas

  • Oncology
  • Obstetrics and Gynecology

Cite this

Evaluation of prognostic factors and treatment modalities in ovarian cancer patients with brain metastases. / Anupol, Noel; Ghamande, Sharad; Odunsi, Kunle; Driscoll, Deborah; Lele, Shashikant.

In: Gynecologic Oncology, Vol. 85, No. 3, 01.01.2002, p. 487-492.

Research output: Contribution to journalArticle

Anupol, Noel ; Ghamande, Sharad ; Odunsi, Kunle ; Driscoll, Deborah ; Lele, Shashikant. / Evaluation of prognostic factors and treatment modalities in ovarian cancer patients with brain metastases. In: Gynecologic Oncology. 2002 ; Vol. 85, No. 3. pp. 487-492.
@article{dde5fac959884c9f97084705216e9036,
title = "Evaluation of prognostic factors and treatment modalities in ovarian cancer patients with brain metastases",
abstract = "Objective. The objective of this study is to evaluate the impact of different clinical variables and treatment modalities on survival in patients with brain metastases from ovarian carcinoma. Methods. Methods included: (1) retrospective chart review of all patients with ovarian cancer and brain metastases from 1986 to 2000 at Roswell Park Cancer Institute and (2) Medline search was performed to extract data from all published reports with three or more cases of ovarian cancer with brain metastases. Cox regression analysis, Kaplan-Meier test, and log rank test were used to calculate survival and compare the impacts of clinical variables and treatment modalities. Results. Fifteen patients with brain metastases out of 1042 women with ovarian carcinoma were identified from our institution, an incidence of 1.4{\%}. The median time from initial diagnosis to detection of brain metastases was 22 months. Patients who were not treated after brain metastasis had a median survival of 0.5 month versus 6 months with therapy. In the subgroup of patients treated with a combination of radiation, surgery, and chemotherapy, the median survival was 22 months. Literature analysis combined with our data generated 124 patients. The only clinically significant variable impacting survival was the presence or absence of additional distant recurrence with median survivals of 3 and 8 months, respectively (P = 0.005). Among patients who received treatment, the combination of radiation and surgery with or without chemotherapy appears to be beneficial, with a median survival of 20 months (P < 0.001). Conclusion. Patients with brain metastases from ovarian cancer without any evidence of disease in other sites appear to benefit from aggressive combined treatment with external radiation and surgery with or without chemotherapy with a median survival of 20 months.",
keywords = "Brain metastases, Brain recurrence, Multimodality treatment, Ovarian carcinoma, Treatment of brain metastases",
author = "Noel Anupol and Sharad Ghamande and Kunle Odunsi and Deborah Driscoll and Shashikant Lele",
year = "2002",
month = "1",
day = "1",
doi = "10.1006/gyno.2002.6653",
language = "English (US)",
volume = "85",
pages = "487--492",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "3",

}

TY - JOUR

T1 - Evaluation of prognostic factors and treatment modalities in ovarian cancer patients with brain metastases

AU - Anupol, Noel

AU - Ghamande, Sharad

AU - Odunsi, Kunle

AU - Driscoll, Deborah

AU - Lele, Shashikant

PY - 2002/1/1

Y1 - 2002/1/1

N2 - Objective. The objective of this study is to evaluate the impact of different clinical variables and treatment modalities on survival in patients with brain metastases from ovarian carcinoma. Methods. Methods included: (1) retrospective chart review of all patients with ovarian cancer and brain metastases from 1986 to 2000 at Roswell Park Cancer Institute and (2) Medline search was performed to extract data from all published reports with three or more cases of ovarian cancer with brain metastases. Cox regression analysis, Kaplan-Meier test, and log rank test were used to calculate survival and compare the impacts of clinical variables and treatment modalities. Results. Fifteen patients with brain metastases out of 1042 women with ovarian carcinoma were identified from our institution, an incidence of 1.4%. The median time from initial diagnosis to detection of brain metastases was 22 months. Patients who were not treated after brain metastasis had a median survival of 0.5 month versus 6 months with therapy. In the subgroup of patients treated with a combination of radiation, surgery, and chemotherapy, the median survival was 22 months. Literature analysis combined with our data generated 124 patients. The only clinically significant variable impacting survival was the presence or absence of additional distant recurrence with median survivals of 3 and 8 months, respectively (P = 0.005). Among patients who received treatment, the combination of radiation and surgery with or without chemotherapy appears to be beneficial, with a median survival of 20 months (P < 0.001). Conclusion. Patients with brain metastases from ovarian cancer without any evidence of disease in other sites appear to benefit from aggressive combined treatment with external radiation and surgery with or without chemotherapy with a median survival of 20 months.

AB - Objective. The objective of this study is to evaluate the impact of different clinical variables and treatment modalities on survival in patients with brain metastases from ovarian carcinoma. Methods. Methods included: (1) retrospective chart review of all patients with ovarian cancer and brain metastases from 1986 to 2000 at Roswell Park Cancer Institute and (2) Medline search was performed to extract data from all published reports with three or more cases of ovarian cancer with brain metastases. Cox regression analysis, Kaplan-Meier test, and log rank test were used to calculate survival and compare the impacts of clinical variables and treatment modalities. Results. Fifteen patients with brain metastases out of 1042 women with ovarian carcinoma were identified from our institution, an incidence of 1.4%. The median time from initial diagnosis to detection of brain metastases was 22 months. Patients who were not treated after brain metastasis had a median survival of 0.5 month versus 6 months with therapy. In the subgroup of patients treated with a combination of radiation, surgery, and chemotherapy, the median survival was 22 months. Literature analysis combined with our data generated 124 patients. The only clinically significant variable impacting survival was the presence or absence of additional distant recurrence with median survivals of 3 and 8 months, respectively (P = 0.005). Among patients who received treatment, the combination of radiation and surgery with or without chemotherapy appears to be beneficial, with a median survival of 20 months (P < 0.001). Conclusion. Patients with brain metastases from ovarian cancer without any evidence of disease in other sites appear to benefit from aggressive combined treatment with external radiation and surgery with or without chemotherapy with a median survival of 20 months.

KW - Brain metastases

KW - Brain recurrence

KW - Multimodality treatment

KW - Ovarian carcinoma

KW - Treatment of brain metastases

UR - http://www.scopus.com/inward/record.url?scp=0036089312&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036089312&partnerID=8YFLogxK

U2 - 10.1006/gyno.2002.6653

DO - 10.1006/gyno.2002.6653

M3 - Article

C2 - 12051879

AN - SCOPUS:0036089312

VL - 85

SP - 487

EP - 492

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 3

ER -